Premium
BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension
Author(s) -
Aldred Micheala A.,
Vijayakrishnan Jairam,
James Victoria,
Soubrier Florent,
GomezSanchez Miguel A.,
Martensson Gunnar,
Galie Nazzareno,
Manes Alessandra,
Corris Paul,
Simonneau Gerald,
Humbert Marc,
Morrell Nicholas W.,
Trembath Richard C.
Publication year - 2006
Publication title -
human mutation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 162
eISSN - 1098-1004
pISSN - 1059-7794
DOI - 10.1002/humu.9398
Subject(s) - haploinsufficiency , biology , genetics , exon , multiplex ligation dependent probe amplification , locus (genetics) , bmpr2 , gene , mutation , genetic linkage , phenotype , bone morphogenetic protein
Mutations of the BMPR2 gene predispose to pulmonary arterial hypertension (PAH), a serious, progressive disease of the pulmonary vascular system. However, despite the fact that most PAH families are consistent with linkage to the BMPR2 locus, sequencing only identifies mutations in some 55% of familial cases and between 10% and 40% of cases without a family history (idiopathic or IPAH). We therefore conducted a systematic analysis for larger gene rearrangements in panels of both familial and idiopathic PAH cases that were negative on sequencing of coding regions. Analysis of exon dosage across the entire gene using Multiplex Ligation‐dependent Probe Amplification identified nine novel rearrangements and enabled full characterization at the exon level of previously reported deletions. Overall, BMPR2 rearrangements were identified in 7 of 58 families and 6 of 126 IPAH cases, suggesting that gross rearrangements underlie around 12% of all FPAH cases and 5% of IPAH. Importantly, two deletions encompassed all functional protein domains and are predicted to result in null mutations, providing the strongest support yet that the predominant molecular mechanism for disease predisposition is haploinsufficiency. Dosage analysis should now be considered an integral of part of the molecular work‐up of PAH patients. © 2006 Wiley‐Liss, Inc.